Randomized trials of mammography have demonstrated the efficacy of mammographic screening for breast cancer in terms of preventing deaths, but various issues of particular interest remain, including: quantification of overdiagnosis; evaluation of service screening outside the research setting; absolute benefit in terms of number needed to screen per life saved; which types of tumours benefit most from early detection; use of screening data to investigate tumour biology and natural history. This paper describes examples of approaches to the above issues, along with some important results.
B
reast cancer screening trials show that regular mammographic screening reduces mortality from breast cancer. [1] [2] [3] It is not the purpose of this paper to discuss the furore over the recent Danish Cochrane review of mammographic surgery. 4 The trialists have answered the criticisms of the review and the consensus remains that mammographic screening significantly reduces mortality from breast cancer (see Figure 1 ) -the arguments are fully and eloquently summarized by Freedman et al. 3 Instead, this paper considers some issues of ongoing interest in the area of mammographic screening.
SOURCES OF DATA AND RESULTS
Much of the material which follows draws on the data from the Swedish Two-County Trial of mammographic screening. In the previously little-known Swedish town of Falun, medical history was made in 1985 with the first publication of mortality results from a trial of breast cancer screening using screen-film mammography as the only screening modality. 5 In this trial, 77,080 women aged 40-74 were randomized to invitation to regular mammographic screening (active study population [ASP] ) and 55,985 to no invitation (passive study population [PSP] ). Women aged 40-49 were invited every two years on average and women aged 50-74 were invited every 33 months. After approximately seven years of screening, the PSP were invited to screening and the trial closed. In the course of the trial 2486 cancers were diagnosed, 1426 in the ASP and 1042 in the PSP. We now have more than 20 years' maximum follow-up on these cases.
Other data sources referred to include cohorts undergoing routine service screening (not as part of a randomized trial) in Sweden and Florence. Some results from a case-control study of breast screening in Wales are also presented.
OVERDIAGNOSIS
In the context of breast cancer screening, overdiagnosis is the detection by screening of cancers which would never have come to clinical attention had screening not taken place. This is not to be confused with what are usually referred to as 'false positives' in a screening programme. By false positives, we mean subjects who are recalled for further assessment of a suspicious mammogram, but for whom the result of that further assessment is a diagnosis of normal or benign tissue. On the other hand, overdiagnosis is the diagnosis, as a result of a screen, of a tumour that is confirmed to be cancer after excision and microscopic examination, which would not have given rise to clinical symptoms or problems during the host's lifetime.
At its most extreme form, overdiagnosis could in theory be a result of diagnosis of a tumour which is biologically incapable of further progression, or indeed which would have regressed spontaneously. A less controversial form of overdiagnosis would be the diagnosis of a potentially progressive cancer in a subject who subsequently dies of another cause (for example, a road traffic accident) before the cancer would have given rise to symptoms.
It is clear that the latter situation must occur, albeit very occasionally, and the former situation is at least theoretically possible. Given the existence of overdiagnosis in principle, the questions remain as to its extent, and how to measure it.
In the first instance, it should be clear that observation of an increase in breast cancer incidence when screening is initiated (as is almost invariably observed) is not of itself evidence of overdiagnosis. The various potential reasons for such an observed increase in incidence are:
(1) A pre-existing trend of increasing incidence. In the late 20th century, breast cancer incidence was increasing in almost every area of the world, particularly in the years before screening started. (2) At the start of any screening programme, there is an observed increase in incidence due to the detection of a large number of prevalent occult cases. Typically, a prevalence (first) screen will detect a number of cancers equivalent to approximately three years' incidence. (3) A periodic rise in incidence with subsequent screenings thereafter, balanced by deficits in incidence in the intervals between screens.
(4) A continuing excess in age-specific incidence due to lead-time. Incidence of breast cancer increases with age. If the effect of screening is to detect tumours on average two years earlier, we will observe the incidence for age 52 at age 50, the incidence for age 53 at age 51, and so on. Figure 2 shows the incidence of breast cancer in England and Wales in 1985, before the screening programme, and in 1995, around the time the screening programme achieved full coverage of invitation of the target population (age group 50-64). The figure shows an increased incidence independent of screening from the differences between the incidence curves outside the two vertical bars, which mark the age limits of the screening programme. One naturally observes the vertical distance between the two curves, but part of the difference is due to leadtime (i.e. to a difference in the horizontal plane). The lead-time may also be responsible for the drop in incidence around age 70, five years after screening has ceased to be offered. (5) In addition, there will always be an observed increased incidence around the lower age limit for screening due to prevalence screens of women reaching the lower age limit. (6) There is probably some overdiagnosis.
The Florence screening programme gives an opportunity to estimate overdiagnosis after removing the tumours anticipated due to lead-time. This programme collected data on a population of 60,000 women aged 50-69, with incidence in 1985-1989 before screening began and in 1990-1999 after the screening programme was initiated. 6 For a screen-detected cancer in the latter period, the probability that it would have arisen clinically after the end of the period of observation is P(t) ¼ e Àlt , where t is the time from diagnosis to 31 December 1999, and 1/l is the mean sojourn time, or the average duration of the preclinical screen-detectable period. This formula assumes an exponential distribution of sojourn time, which has been shown to give a good fit to breast screening data in the past. 7 Summing the P(t) estimates over all screen-detected breast cancers gives an estimate of the expected excess of cancers in the period 1990-1999 due to early detection of tumours which would have occurred after 1999, but which are not overdiagnosed cases. There is a correction for this to remove cases which would have occurred after the expected remaining lifetime of the subjects, since these do constitute overdiagnosis, but this is very small.
The results are shown in Table 1 . Among invasive cancers only, an apparent 11% excess in the screening epoch becomes a non-significant 2% excess when the anticipated cancers are removed. Thus, there is no strong evidence for overdiagnosis of invasive cancers. When all tumours, including DCIS, are included, there is a significant 5% excess even after removing the anticipated cancers. Thus there is evidence of modest overdiagnosis, mainly due to DCIS.
To further investigate this, a mover-stayer model was fitted to screening data to estimate the proportion of DCIS which is overdiagnosed. 8 An individual may move from state 'no disease' to state 'non-progressive DCIS', or to 'progressive DCIS'. If she moves to the former, further disease progression is impossible. If the disease is then detected at a screen, this is overdiagnosis. If she moves to the latter state she may then progress further to preclinical invasive disease, and from there to clinical invasive disease.
The parameters of the model were estimated using screening data from Sweden, the UK, the USA, the Netherlands and Australia. The implications of the results are summarized in Table 2 . The figure of 37% of DCIS being overdiagnosed at first screen sounds excessive, but one should consider that since DCIS constitutes a minority of cancers detected at screening, this means that only one cancer in 20 is overdiagnosed at first screen. At the second and third screens, only 4% of DCIS cases are estimated to be Table1 Incidence in the Florence screening programme, incidence expected, estimated anticipated tumours due to lead time, and corrected estimate of relative excess Current issues in breast cancer screening non-progressive, implying that around one in 175 of all cancers diagnosed at second and subsequent screens is overdiagnosed. Put in absolute terms, this means that a woman attending a first screen has a one in 3300 chance of having an overdiagnosed cancer, and a woman attending a second or subsequent screen has a one in 50,000 chance of having an overdiagnosed cancer.
There is a good deal of uncertainty around these estimates, and therefore considerable scope for further research to quantify the problem of overdiagnosis. In the meantime, however, it appears to be a minor phenomenon, mainly confined to DCIS, and does not contraindicate screening.
EVALUATION OF SERVICE SCREENING WITH MAMMOGRAPHY
Despite the positive results of the randomized controlled trials of breast cancer screening, there remains the task of evaluating the mammographic screening programmes which have been springing up worldwide since the late 1980s. The effects of service screening may differ from those of the trials due to different target populations, different levels of expertise among the clinical and support personnel involved, improvements to the imaging technology since the trials and differences in quality of service delivery due to factors of scale. In any case, when a medical innovation is introduced at community level, there is a period of observation (in the case of a pharmaceutical agent known as the post-marketing surveillance era), in which we ascertain whether the innovation is being delivered in the correct form to the correct target population. This period is just as important in primary and secondary prevention as it is in the treatment of disease.
There are numerous measures of the screening process which are essential to quality control. The most important evaluation task, however, must be the estimation of the effect of the intervention, in this case mammographic screening, on the clinical outcome to be prevented (death from breast cancer). Three broad strategies are available, each with its own advantages and problems. These are discussed below.
Invited:not yet invited comparison
When a screening programme is introduced, it often takes several years to achieve coverage of the target population. This provides a time window in which two contemporaneous populations are available: subjects invited and subjects not yet invited to screening. Death rates from tumours diagnosed in the two groups can be compared. Provided the order of invitation is not related to factors which influence risk (e.g. age or socioeconomic status), the comparison has a validity approaching that of a randomized trial. The disadvantage of this strategy is the fact that the time window of opportunity is usually short, leading to small numbers of cases and deaths, and therefore low sensitivity of the comparison. It should also be borne in mind that it gives an intention-to-treat estimate of the effect of being invited to screening, rather than of being screened.
Before:after comparison
A powerful method of evaluation is the comparison of breast cancer death rates in a given region before and after the introduction of screening. The method does need to cope with problems of classification of screening exposure (deaths in the screening epoch may be from tumours diagnosed in the pre-screening epoch which could not possibly have benefited from screening), and confounding with other changes over time. These can be addressed by design and analytical refinements. 9 The design can also incorporate estimation of the effect of being screened rather than being invited. 9 This in turn gives rise to self-selection bias, which requires analytical solution. 10
Case--control studies
The case-control evaluation takes subjects who have died of the disease (cases), selects comparison subjects who have not died (controls) and compares the screening histories of the two. 11 If screening is effective in reducing mortality, the controls will have a stronger screening history than the cases. This retrospective design has the advantages of being cheap and rapid. It is, however, prone to various biases, correcting for which leads to complexity of design, analysis and interpretation. 11 Table 3 shows the results of three studies exemplifying the designs described above in which the Cancer Research UK group in the Wolfson Institute has participated. 9, 12, 13 The results show a degree of consistency, with an estimated breast cancer mortality reduction of 25% associated with invitation to screening and 25-48% with actually being screened.
ABSOLUTE BENEFIT OF SCREENING
A possible measure of the absolute benefit of an intervention is the number needed to treat to save one life (in this case, the number needed to screen). In the past, rather high numbers have been quoted, of the order of 1000-1500 needed to screen for 10 years to save a single life. 14 These figures are inaccurate for two principal reasons. In the first instance, they confuse invitation to screening with screening itself. When estimating the absolute benefit of screening, it is important to distinguish being invited to screening from actually being screened, as a number of invited women do not attend.
Secondly, they confuse the period of follow-up with period of screening. In a screening trial, screening is typically offered for a relatively short period (in most trials ranging from five to eight years). This period is referred to as the screening phase. The breast cancers diagnosed during this period are followed up thereafter for mortality from breast cancer. Previous estimates have incorrectly assumed that the period of follow-up is equal to the screening phase. For an accurate estimate of the benefit, it is vital to have sufficiently long follow-up to observe the benefit (put rather coldly, there needs to be enough time for cases to die), but also to bear in mind the length of the screening phase in interpreting the estimate. Table 4 illustrates the calculation of the absolute benefit from the Swedish Two-County Trial. 15 The cumulative breast cancer death rate in the ASP was 4.14 per 1000, that in the PSP 5.97. We would therefore expect 0.00597 Â 77,080 ¼ 460 deaths in the ASP if the screening had no effect on breast cancer mortality. Instead, 319 deaths were observed: 141 deaths were prevented. If 77,080 were divided by this figure, it would give 547 women needed to invite to save one life. However, on average 15% of women did not attend for screening, so that there were 65,518 women actually screened. The number needed to screen to save one life is therefore estimated as 65,518/141 ¼ 465. The screening phase of the Swedish Two-County Trial was around seven years. Screening 1000 women for 10 years would therefore be estimated to save around three lives.
The method above respects the randomization and uses the intention-to-treat estimate of the benefit. It divides this benefit by the screening activity, rather than the invitation activity, required to achieve the benefit, analogous to the causal estimate of Baker et al. 16 It may be argued that the number needed to invite is relevant to policy decisions. If so, it needs to be borne in mind that the number needed to invite will be specific to the population concerned, depending as it does on the attendance rate in that population.
WHICH TUMOURS BENEFIT MOST FROM SCREENING?
The issue of the potential benefit from detecting DCIS in screening programmes is a perennial source of controversy. In a recent paper, 17 we addressed this issue using the Two-County Study data to estimate:
(1) the shift in the ASP from stage II or worse (stage II þ ) invasive cancer to stage I invasive cancer; (2) the shift from stage I invasive cancer to DCIS;
(3) the 20-year fatality rates pertaining to DCIS, stage I invasive cancer, and stage II þ invasive cancer; (4) by combining the fatality rates with the stage shifts, the numbers of deaths prevented as a result of detection of early invasive disease and as a result of detection of DCIS. Table 5 shows the cumulative rates of DCIS, stage I invasive cancer, and stage II þ invasive cancer with the corresponding 20-year fatality rates of these tumours.
The number of tumours estimated to have been stage-shifted from stage II þ to stage I as a result of early detection is: 9.91 Â 77.08À524 ¼ 764-524 ¼ 240
The number of lives saved as a result of such downshifting is estimated from the fatality rates in the table, such that: 240 Â (0.55-0.17) ¼ 91 13 Case-control Screening (ever) 25% Sweden 9 Before/after Screening (regular) 48% The number of tumours shifted from invasive to DCIS is estimated as:
17.79 Â 77.08-1303 ¼ 1371-1303 ¼ 68 Assuming that such stage-shifting to DCIS came only from stage I tumours, the number of lives saved as a consequence is estimated as:
68 Â (0.17-0.06) ¼ 7 There were 141 lives saved in total in the ASP (see above). Thus, 65% (91/141) of the deaths prevented were as a result of detection of frank invasive disease at stage I, and 5% (7/ 141) were as a result of the detection of DCIS. The remaining lives saved are likely to be from residual stageshifts within stage II þ and stage I. Varying the assumptions to allow 10% of the tumours shifted to DCIS to be from cases which would otherwise have been invasive stage II þ gives 12% of deaths avoided being due to detection of DCIS.
These results suggest that the overwhelming majority of the observed benefit of mammographic screening is due to the detection of small invasive tumours. This does not mean that DCIS should not be diagnosed or treated. It does imply, however, that the detection of small invasive cancers should be the focus of training and quality control in screening programmes. Because DCIS is usually manifested as calcifications on the mammogram, it is relatively easy to detect. A programme with adequate sensitivity to detect small invasive lesions will therefore also be of sufficient quality to detect DCIS.
USE OF SCREENING DATA TO INVESTIGATE NATURAL HISTORY
The mammographic screening trials afforded the scientific community the opportunity for the first time to study the biology, behaviour, and natural history of breast cancers diagnosed and treated at an early stage. Several issues have been investigated by a number of researchers, but this paper concentrates on two.
The first of these is the phenomenon of dedifferentiation or phenotypic drift. A question of some interest in the 1990s was whether the histological grade of a tumour is innate and immutable or whether it changes as the tumour develops. Grade is a score corresponding to the aggressive potential of the cancer, determined on microscopic examination of the excised tumour by a pathologist. It comprises elements based on tubule formation (differentiation), pleomorphism and mitotic activity.
Observations of these features are combined into a threepoint scale. Grade 1 corresponds to tumours with good prognosis, grade 3 to aggressive, rapidly growing tumours with traditionally poor prognosis, and grade 2 to intermediate aggressive potential and therefore intermediate prognosis. If, in a screening trial, the group offered screening had a lower absolute rate of grade 2 or 3 tumours than the control group, this would constitute evidence that these had been avoided as a result of early detection, and therefore that, for some tumours at least, the grade worsens as the tumour develops. Note that a larger number of grade 1 tumours would not itself constitute sufficient evidence, since this might be a product of length bias or overdiagnosis.
An alternative method to avoid the effects of length bias and overdiagnosis is to compare the grade distribution of the ASP with PSP, excluding the cancers diagnosed at first screen of the ASP at the beginning of the study and those diagnosed at the first screen of the PSP at the end of the study. This gives two sets of incident tumours which are comparable in all respects except for earlier detection in the ASP. 18 Using this method, there is indeed a significant deficit in grade 3 cancers in the ASP. 18 On the other hand, if all tumours are considered, however they were diagnosed, there is evidence of dedifferentiation. In total, there were 903 grade 2 or 3 cancers in the ASP and 734 in the PSP. The relative risk of grade 2 or 3 cancer is therefore:
with a 95% confidence interval of (0.80, 0.99), a significant 11% deficit in grade 2 and 3 breast cancers in the ASP. One mechanism whereby dedifferentiation might occur is intratumour heterogeneity. Suppose a tumour is detected by screening at size 10 mm and excised. Suppose further that the pathologist finds the tumour to be grade 1, but with parts which appear to be grade 3. The decision based on the majority of cancer tissue observed is grade 1. If, however, the tumour had not been detected at size 10 mm but been allowed to grow to, say, 30 mm before excision, the grade 3 portion would have been likely to grow faster than the grade 1 portion. Thus, at size 30 mm, the same tumour may have been classified as grade 3. Whatever the mechanism, it appears that dedifferentiation does indeed occur in some tumours. This emphasizes another possible advantage of early detection: that of diagnosis and treatment before the tumour's maximum aggressive potential has been reached.
Another issue of natural history is the effect of casting calcifications (linear, branching patterns of calcification observed on a mammogram) on survival in small breast cancers. The vast majority of invasive breast tumours of o15 mm have excellent prognosis, with 20-year survival in the region of 90%. 19 The question remains as to why a small number of cases have poor survival. Within this group of small tumours, the usual prognostic factors (size, node status, and histological grade) have limited prognostic value. 19 A factor which is strongly related to survival in these cases is casting calcifications. Figure 3 shows survival in 709 invasive breast cancers by mammographic appearance. 20 The presence of casting calcifications is associated with an approximate 10-fold increase in risk of death from breast cancer. Fortunately, such cases are rare, making up 7% of the cases of size 1-14 mm (and an even smaller proportion of larger tumours). It is a sobering thought that 38% of the deaths occur in this group of 7% of the cases. In very small tumours 20 The most frequently observed pathological correlate of casting calcifications is the presence of high-grade DCIS in the vicinity of the small invasive tumour. The Wolfson Institute, in collaboration with colleagues at Barts and elsewhere, is working on studies of the biological and molecular features of these tumours. Results will be used to formulate hypotheses about treatment of these cases, for which there is an urgent need.
FUTURE ANALYTICAL ISSUES IN CANCER SCREENING
There is a clear need for innovative analytical approaches to evaluation of service screening programmes, notably in breast and colorectal screening. A potentially productive strategy is the design of multicentre studies, finding attributes of the screening programmes in different centres which best account for the variation in effectiveness between centres. In this area, meta-regression and institutional comparison techniques 21, 22 are promising analytical approaches.
Another analytical challenge which is likely to arise in the future is the monitoring and evaluation of individualized screening programmes. For example, women with radiologically dense breasts might be offered other screening modalities in addition to mammography, or, in colonoscopy programmes, the frequency of examination might depend on the magnitude of the subject's risk as determined by findings at previous colonoscopies.
There will also be a need for methods of rapid evaluation of new screening technologies. A current example is the UK study of mammography against magnetic resonance imaging in women at high familial or genetic risk of breast cancer. 23 This study is one in which all subjects receive both screening modalities, with a matched pair comparison, and the endpoint of interest is sensitivity of the screening tool to cancers. The contribution of matched design and analysis with the sensitivity endpoint yields a result long before a traditional comparative trial with a mortality endpoint would have done. In the years to come, there will be an increasing emphasis on molecular and other biological markers as screening tools.
CONCLUSION
If effective and safe means of primary prevention of cancers can be found, this would be the strategy of choice for control of the disease. Where such methods are not available, screening to enable treatment at a stage when it is likely to be successful can be an attractive alternative. Mammographic screening for breast cancer is an excellent example of an effective and well-evaluated cancer-screening tool.
